Recent Press Releases

Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion

2014 Revenue and Adjusted EPS Guidance Reaffirmed

THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

- Potential Therapeutic Candidates Now Identified for All Three GSK Collaboration Targets - CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Epizyme, Inc. EPZM +15.39% , a clinical stage...

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

- Proceeds will Further Strengthen Avalanche's Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration - MENLO PARK, Calif., April 22, 2014...

Principia Biopharma Secures $50 Million Series B Financing

Proceeds enable expansion into a clinical stage company April 22, 2014 08:30 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Principia Biopharma Inc. today announced that it...

ProNAi Therapeutics Raises $59.5 Million Series D Financing

Proceeds Will Advance Clinical Studies of Its BCL2 Targeted Cancer Drug and Other Pipeline Candidates April 21, 2014 PLYMOUTH, MICH. — ProNAi Therapeutics, Inc., a developer of novel nucleic...

ENANTA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO THE U.S. FDA FOR ALL-ORAL, INTERFERON-FREE HEPATITIS C REGIMEN

AbbVie's submission to FDA triggers $20 million milestone payment to Enanta Regimen includes Enanta's and AbbVie's protease inhibitor ABT-450 WATERTOWN, Mass.--Apr. 22, 2014-- Enanta...

ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ITS INVESTIGATIONAL, ALL-ORAL, INTERFERON-FREE THERAPY FOR THE TREATMENT OF HEPATITIS C

-SUBMISSION BASED ON THE LARGEST PHASE III PROGRAM IN GENOTYPE 1 (GT1) HEPATITIS C PATIENTS CONDUCTED TO DATE(1) -ABBVIE'S INVESTIGATIONAL REGIMEN WAS DESIGNATED AS A BREAKTHROUGH THERAPY BY...

FDA approves Cyramza for stomach cancer

The U.S. Food and Drug Administration today approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the...

Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal

NEW YORK, April 15, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical...

Tokai Pharmaceuticals Appoints Karen J. Ferrante, M.D. as Head of R&D and Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer and other hormonally driven diseases, today...

WuXi PharmaTech Co., Ltd. Announces Management Appointments

SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and...

Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

SAN DIEGO, April 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...

23andMe Appoints Dr. Jill Hagenkord Chief Medical Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--23andMe, the leading personal genetics company, today announced the appointment of Dr. Jill Hagenkord as chief medical officer. Hagenkord will be responsible...

Astellas Pharma US Promotes Jeffrey Bloss To SVP Of Medical Affairs For The Americas

NORTHBROOK, Ill., April 16, 2014 /PRNewswire/ -- Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced Jeffrey D. Bloss, M.D., has been promoted to the position...

Winston R. Brown, Jr. Joins Alexza Pharmaceuticals, Inc. (ALXA) As Vice President, Quality

MOUNTAIN VIEW, Calif., April 17, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Winston R. Brown, Jr. has joined the Company as Vice President, Quality. Mr....

XBiotech USA, Inc. Welcomes Addition Of Senior Vice President Corporate Development & General Counsel

AUSTIN, Texas, April 15, 2014 /PRNewswire/ -- XBiotech announced today that Robert Lindsey has joined the Company as Senior Vice President Corporate Development & General Counsel. Mr. Lindsey...

AIT Laboratories Names Vice President Of Science And Technology

INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- AIT Laboratories (AIT) has named Kun Ma, MD, Ph.D., MBA to the position of vice president of science and technology. Dr. Ma comes to the company after...

Sanovas Appoints Jeff Heer As Chief Operating Officer

SAUSALITO, Calif., April 14, 2014 /PRNewswire/ -- Sanovas Inc., a Life Sciences Accelerator developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery...

BioRestorative Therapies Appoints Wayne Olan, M.D. to Scientific Advisory Board

JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for...

Kite Pharma, Inc. Expands Leadership Team And Announces Senior Management Promotions

SANTA MONICA, Calif., April 14, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products...